



Racial and ethnic disparities in breast cancer survival: critical appraisal of the data emerging from the randomized TAILORx

Gianluca Franceschini, Armando Orlandi

Multidisciplinary Breast Unit, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Correspondence to: Gianluca Franceschini. Multidisciplinary Breast Unit, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. Email: gianlucafranceschini70@gmail.com.

Comment on: Albain KS, Gray RJ, Makower DF, *et al.* Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. *J Natl Cancer Inst* 2021;113:390-9.

Submitted Sep 29, 2022. Accepted for publication Oct 19, 2022.

doi: 10.21037/atm-2022-64

View this article at: <https://dx.doi.org/10.21037/atm-2022-64>

Breast cancer is recognized as a transnational precedence in health care; it's presently the most frequent cancer in women in the world with epidemiological data showing a continuous increase in incidence (1).

Despite the benefits of advances in early detection and treatment of breast cancer have contributed to improve clinical outcomes in our patients, the ethnical difference in survival has increased (2); various studies have reported that Black race is associated with a worse prognosis compared to the White race and that this disparity persists over time (2-13).

Many factors have been postulated as possible determinants of higher mortality rates in Black women reported in previously studies (2-13) such as:

- ❖ Higher probability of having advanced stage and triple negative breast cancer in Black women.
- ❖ Non-guideline-adherent primary management with incomplete, discontinuous or delayed receipt of locoregional treatment, chemotherapy, or endocrine therapy for Black patients.
- ❖ More comorbidities in Black women.
- ❖ Disparities in care with use of non-standard or underdosing therapies for Black patients.

Despite significant reduction in breast cancer mortality in the last years, these factors may have contributed to the persistent ethnical gap in breast cancer survival (12,13).

In order to detect the factors contributing to this disparity, Kathy S. Albain and colleagues analyzed the clinicopathologic characteristics, the 21-gene recurrence score (RS), treatment delivered, and clinical outcomes by race and ethnicity for 9,719 eligible women with hormone receptor-positive,

HER2-negative, axillary node-negative breast cancer who participated in the “Trial Assigning Individualized Options for Treatment” (TAILORx) (14). In particular, they performed a post hoc analysis of 8,189 (84.3%) Whites, 693 (7.1%) Blacks, 405 (4.2%) Asians, and 432 (4.4%) with other or unknown race; after an adjustment for some covariates, the Authors concluded that compared with White race, with the same RS by OncotypeDx and similar antineoplastic treatments, Black patients have a reduced survival, but like White patients they have no benefit from adjuvant chemotherapy in case of RS between 11 and 25 (14).

This work adds to an arising body of evidence on ethnical difference in breast cancer-specific mortality in hormone receptor-positive disease also when a homogeneous study population by stage and treatment is evaluated. Indeed, this study included patients with luminal-like, HER2-negative, axillary node-negative breast cancer with good performance status who have no significant comorbidities to undergo adjuvant cytotoxic therapy; all women received standard surgical, radiation and systemic treatment and there were no differences in the use of chemotherapy and endocrine therapy by race.

The strength of this work is that for the first time it can be assumed that the racial disparities observed can't be attributed to prognostic gene signature, gene mutations, clinicopathologic features, the type or extension of endocrine and/or cytotoxic therapy, or other clinical covariates, but they should be attributed to potential differing sensitivity to antineoplastic therapy, effective compliance to treatment or other unrecognized reasons.

The intrinsic weakness of the study is its nature: post-hoc analysis, sample not adequately powered to answer the question and some results at the limits of statistical significance or not statistically significant (distant relapse free interval in entire population and overall survival in entire population and RS 11–25 population showed only a trend of worst outcome in the Black patients) (14).

Despite these limitations, the study of Kathy S. Albain and colleagues should serve as a step toward improving the racial/ethnic gap in breast cancer mortality.

Future prospective research that combines epidemiologic, molecular and genomic data must provide appropriate tools in order to reduce the race/ethnicity-based differences in prognosis of breast cancer subtypes (15).

It is important to underline that ethnic disparity in breast cancer is a very complex issue, which includes biological heterogeneity, the presence of different comorbidities and the interaction of various economic, social and behavioural factors.

Removal of biological and access determinants associated with breast cancer mortality is necessary for the development of successful actions.

So, additional clinical trials, specifically designed with greater representation of racial and ethnic minorities, are necessary to verify if there are biological, socioeconomic or other determinants contributing to racial difference in breast cancer-specific survival in hormone receptor-positive disease.

Multiple strategies such as the diffusion of programs for patient education about oncological trials must be implemented in order to increase enrollment of the breast cancer women from minorities groups and to stimulate researchers to always report race and ethnicity of participants.

Meanwhile, adequate implementation of programs of healthy lifestyles, appropriate interventions against diagnosis and treatment delays and improvement of adjuvant therapy adherence among vulnerable populations are needed in order to mitigate the observed disparities in breast cancer mortality.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned

by the editorial office, *Annals of Translational Medicine*. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-2022-64/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Franceschini G, Mason EJ, Franco A, et al. Surgical treatment of breast cancer. *Minerva Surg* 2021;76:495-7.
2. Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. *Nat Rev Dis Primers* 2019;5:66.
3. Joslyn SA, West MM. Racial differences in breast carcinoma survival. *Cancer* 2000;88:114-23.
4. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA* 2006;295:2492-502.
5. Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. *J Clin Oncol* 2005;23:6639-46.
6. Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. *J Clin Oncol* 2003;21:602-6.
7. Tammemagi CM, Nerenz D, Neslund-Dudas C, et al. Comorbidity and survival disparities among black and white patients with breast cancer. *JAMA* 2005;294:1765-72.
8. Menashe I, Anderson WF, Jatoi I, et al. Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. *J Natl Cancer Inst* 2009;101:993-1000.
9. Jatoi I, Becher H, Leake CR. Widening disparity in

- survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system. *Cancer* 2003;98:894-9.
10. Sparano JA, Wang M, Zhao F, et al. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. *J Natl Cancer Inst* 2012;104:406-14.
 11. Schneider BP, Shen F, Jiang G, et al. Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. *JCO Precis Oncol* 2017;2017:PO.17.00059.
 12. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. *CA Cancer J Clin* 2021;71:7-33.
 13. Warner ET, Tamimi RM, Hughes ME, et al. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. *J Clin Oncol* 2015;33:2254-61.
 14. Albain KS, Gray RJ, Makower DF, et al. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. *J Natl Cancer Inst* 2021;113:390-9.
 15. Aldrighetti CM, Niemierko A, Van Allen E, et al. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. *JAMA Netw Open* 2021;4:e2133205.

Cite this article as: Franceschini G, Orlandi A. Racial and ethnic disparities in breast cancer survival: critical appraisal of the data emerging from the randomized TAILORx. *Ann Transl Med* 2022;10(23):1294. doi: 10.21037/atm-2022-64